SELECT Trial The SELECT trial, one of the largest cardiovascular outcomes trials in obesity medicine, enrolled over 17,000 participants with established cardiovascular disease and obesity or overweight (without diabetes) and demonstrated a 20% reduction in MACE with semaglutide 2.4 mg
As a result, you may experience chronic blurred vision or difficulty seeing things at a distance
These molecules, which have made waves in the treatment of obesity and Type 2 diabetes through medications such as Ozempic, Wegovy and Zepbound, are more stable than their natural counterparts, thus increasing their therapeutic potential
Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Dyspepsia (common) Cholelithiasis (common) Headache (common) These gastrointestinal effects typically occur during the initial weeks of treatment or following dose escalation, and often diminish over time as the body adjusts to the medication
As we age or experience illness, stress, or injury, NAD levels naturally declineleading to reduced cellular efficiency and impaired recovery
